Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis

NCT04322708 is registered in ClinicalTrials.gov with Allakos Inc. as lead sponsor.

NCT NCT04322708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04322708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis
Lead sponsor
Allakos Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
July 6, 2020
Completion date
January 18, 2022
Enrollment
277 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis